- Home
- TCRT vs VCNX Comparison
TCRT vs VCNX Comparison
Compare TCRT & VCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRT
- VCNX
- Stock Information
- Founded
- TCRT 1998
- VCNX 2001
- Country
- TCRT United States
- VCNX United States
- Employees
- TCRT N/A
- VCNX N/A
- Industry
- TCRT Biotechnology: Pharmaceutical Preparations
- VCNX Biotechnology: Pharmaceutical Preparations
- Sector
- TCRT Health Care
- VCNX Health Care
- Exchange
- TCRT Nasdaq
- VCNX Nasdaq
- Market Cap
- TCRT 3.8M
- VCNX 4.5M
- IPO Year
- TCRT N/A
- VCNX N/A
- Fundamental
- Price
- TCRT $2.08
- VCNX $3.22
- Analyst Decision
- TCRT
- VCNX
- Analyst Count
- TCRT 0
- VCNX 0
- Target Price
- TCRT N/A
- VCNX N/A
- AVG Volume (30 Days)
- TCRT 14.2K
- VCNX 167.3K
- Earning Date
- TCRT 11-14-2024
- VCNX 11-29-2024
- Dividend Yield
- TCRT N/A
- VCNX N/A
- EPS Growth
- TCRT N/A
- VCNX N/A
- EPS
- TCRT N/A
- VCNX N/A
- Revenue
- TCRT $7,000.00
- VCNX $388,000.00
- Revenue This Year
- TCRT N/A
- VCNX N/A
- Revenue Next Year
- TCRT N/A
- VCNX N/A
- P/E Ratio
- TCRT N/A
- VCNX N/A
- Revenue Growth
- TCRT N/A
- VCNX N/A
- 52 Week Low
- TCRT $1.95
- VCNX $1.39
- 52 Week High
- TCRT $33.00
- VCNX $13.02
- Technical
- Relative Strength Index (RSI)
- TCRT 44.32
- VCNX 48.87
- Support Level
- TCRT $2.00
- VCNX $2.87
- Resistance Level
- TCRT $2.86
- VCNX $3.43
- Average True Range (ATR)
- TCRT 0.17
- VCNX 0.53
- MACD
- TCRT 0.05
- VCNX 0.05
- Stochastic Oscillator
- TCRT 14.29
- VCNX 23.22
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.
About VCNX Vaccinex Inc.
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.